GlassScriptPhysician profile
Brent E Thomason
NPI 1316476401
$7,141.31
in general payments reported to CMS, 2019-2025
44 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $208 · 2021: $869 · 2022: $783 · 2023: $1,234 · 2024: $2,001 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,181.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,634.49 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $772.71 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $630.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $622.99 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $575.80 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $397.94 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $357.42 | 2020-2025 | |
| Amgen INC. | $288.90 | 2020-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.94 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $223.12 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Axsome Therapeutics, INC. | $169.22 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $151.50 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $143.04 | 2021-2024 | Spravato |
| Corium, LLC | $79.83 | 2023-2025 | Azstarys |
| Inari Medical, INC. | $61.09 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Thomason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.